$EVH

Evolent Health (EVH) reported Q2 CY2026 revenue of $652.5 million, up 46.9% year on year, beating Wall Street expectations. Full-year revenue guidance of $2.65 billion at the midpoint was 5.9% above analysts’ estimates. Non-GAAP EPS was $0.02. Management cited Highmark contract launch, renewals, and scaling of its Auth Intelligence AI automation, while noting Medicaid and exchange membership headwinds.

Evolent Health (NYSE:EVH) reported Q2 CY2026 results. Revenue rose 46.9% year on year to $652.5 million, beating Wall Street estimates by 9.4%. Full-year revenue guidance of $2.65 billion at the midpoint was 5.9% above analysts’ forecasts. Non-GAAP EPS was $0.02, above consensus, and EVH shares jumped 18.2% to $3.64.

Evolent Health (EVH) shares rose 23.4% in pre-market after the company reported Q2 2026 results. According to the article, EPS was $0.02 versus -$0.01 expected, and revenue was $652.52M versus $597.46M expected, up about 47% year over year. The move was linked to short interest with days to cover near 5.67 and multiple EPS estimate revisions.

Evolent Health (NYSE: EVH) reported Q2 2026 results for the three months ended June 30, 2026 and raised 2026 revenue guidance to $2.6 to $2.7 billion and Adjusted EBITDA to $120 to $135 million. The company expects 2027 revenue growth of over 25% and Adjusted EBITDA midpoint at or above $150 million. It also outlined two partnership updates, including a $300 million annualized oncology deal.

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2exhibit991.htm EX-99.1 Document Exhibit 99.1 Evolent Announces Second Quarter 2026 Results WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex co

Evolent Health (EVH) reports earnings Thursday before market hours. Last quarter, it posted revenue of $496.2M, up 2.6% YoY, missing analysts’ revenue expectations, while EPS beat. For the upcoming quarter, analysts expect revenue growth of 34.3% YoY. EVH is down 46.1% over the past month versus an average peer gain, with an analyst price target of $5.83.

The article argues that investors should look beyond “Mag Seven” AI hype to S&P 500 companies showing documented AI deployment. It cites a dataset of 130 firms and highlights five: Visa (V), Salesforce (CRM), ServiceNow (NOW), Evolent Health (EVH), and Pagaya (PGY), with figures on AI use, acquisitions, and recent valuation/stock moves.

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evolent Health (EVH) delivered earnings and revenue surprises of -50.00% and +2.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Privia Health Group, Inc. PRVA on Tuesday agreed to acquire an Accountable Care Organization ( ACO ) business from Evolent Health, Inc. EVH. Privia Health will pay $100 million in cash at closing and up to an additional $13 million, subject to final Medicare Shared Savings Program ( MSSP ) ...